NCCM
RARE icon

Nine Chapters Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nine Chapters Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,400
Closed -$522K – 1113
2015
Q1 		$522K Buy
+8,400
New +$467K 0.04% 593

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nine Chapters Capital Management's RARE Position: Q2 2015 in Review

Nine Chapters Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2015, closing a stake of 8,400 shares — an estimated $522K sold.

Nine Chapters Capital Management first reported a position in RARE in Q1 2015 and held it in 1 quarter. The position peaked at $522K in Q1 2015. 151 funds tracked by Wall St. Rank hold RARE as of Q2 2015.

  • Nine Chapters Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 8,400 Ultragenyx Pharmaceutical shares in Q2 2015, an estimated $522K.
  • Nine Chapters Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Ultragenyx Pharmaceutical position peaked at $522K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2015.

Based on Nine Chapters Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.